CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS: CNBX · Delayed Price · USD
0.0100
0.00 (0.00%)
Aug 30, 2024, 4:00 PM EDT - Market closed
CNBX Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | May '24 May 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | Aug '20 Aug 31, 2020 | Aug '19 Aug 31, 2019 | 2018 - 2014 |
| Revenue | 0.23 | 0.41 | 0.03 | - | 0.01 | 0.01 | Upgrade
|
| Revenue Growth (YoY) | -32.36% | 1269.13% | - | - | -27.29% | 2.52% | Upgrade
|
| Gross Profit | 0.23 | 0.41 | 0.03 | - | 0.01 | 0.01 | Upgrade
|
| Selling, General & Admin | 0.56 | 0.91 | 1.8 | 0.83 | 1.37 | 1.77 | Upgrade
|
| Research & Development | 0.36 | 0.43 | 1.18 | 1.77 | 1.68 | 1.54 | Upgrade
|
| Operating Expenses | 0.92 | 1.34 | 2.98 | 2.6 | 3.05 | 3.31 | Upgrade
|
| Operating Income | -0.69 | -0.93 | -2.95 | -2.6 | -3.04 | -3.3 | Upgrade
|
| Interest Expense | -0.04 | -0 | -0 | -0 | -0.01 | -0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | 0 | -0.06 | -0.02 | -0.06 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.05 | -0.05 | -0.72 | -0.96 | -4.42 | 4.36 | Upgrade
|
| EBT Excluding Unusual Items | -0.79 | -0.98 | -3.74 | -3.59 | -7.54 | 1.06 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0.2 | 0.07 | 0.07 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.42 | -2.73 | 0.01 | 0.2 | - | - | Upgrade
|
| Pretax Income | -1.21 | -3.71 | -3.72 | -3.19 | -7.47 | 1.13 | Upgrade
|
| Earnings From Continuing Operations | -1.21 | -3.71 | -3.72 | -3.19 | -7.47 | 1.13 | Upgrade
|
| Net Income | -1.21 | -3.71 | -3.72 | -3.19 | -7.47 | 1.13 | Upgrade
|
| Net Income to Common | -1.21 | -3.71 | -3.72 | -3.19 | -7.47 | 1.13 | Upgrade
|
| Shares Outstanding (Basic) | 28 | 9 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 9 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 749.35% | 621.77% | 5.92% | 2.95% | 1.59% | 10.03% | Upgrade
|
| EPS (Basic) | -0.04 | -0.42 | -3.05 | -2.77 | -6.66 | 1.03 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.42 | -3.05 | -2.77 | -6.66 | 1.03 | Upgrade
|
| Free Cash Flow | -0.18 | -0.11 | -1.68 | -2.49 | -2.85 | -3.31 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -1.37 | -2.16 | -2.54 | -3.00 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | - | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -300.82% | -227.07% | -9860.37% | - | -42524.13% | -33563.01% | Upgrade
|
| Profit Margin | -525.12% | -904.57% | -12428.23% | - | -104337.91% | 11510.41% | Upgrade
|
| Free Cash Flow Margin | -76.80% | -27.43% | -5610.68% | - | -39830.98% | -33634.70% | Upgrade
|
| EBITDA | -0.58 | -0.77 | -2.76 | -2.38 | -2.83 | -3.11 | Upgrade
|
| EBITDA Margin | -252.65% | -187.56% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.11 | 0.16 | 0.2 | 0.22 | 0.22 | 0.19 | Upgrade
|
| EBIT | -0.69 | -0.93 | -2.95 | -2.6 | -3.04 | -3.3 | Upgrade
|
| EBIT Margin | - | -227.07% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.